Mikhail Rojavin

Mikhail Rojavin is a Senior Scientific Director in Clinical Development at Amgen, a position held since October 2023 following the acquisition of Horizon, where Mikhail also served in the same role since September 2022. Prior to joining Horizon, Mikhail was a Global Clinical Program Director at CSL Behring from February 2006 to September 2022, managing clinical programs and engaging with regulatory authorities including the FDA and EMA. Mikhail's earlier experience includes work as a Clinical Team Leader at Novartis Pharma, a Senior Clinical Research Associate at Omnicare Clinical Research, and an Assistant Professor at Temple University School of Medicine. Mikhail holds a Postdoctoral degree in Pharmacology from Temple University and a Ph.D. in Microbiology from the Ukrainian National Academy of Sciences. Mikhail also founded the Autovaccine Research Center, focused on developing autovaccines for chronic bacterial infections.